Trial Profile
A randomized, open-label, study of nelfinavir or efavirenz in HIV-1 infected, antiretroviral naive patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Nelfinavir (Primary) ; Didanosine; Efavirenz; Keyhole limpet haemocyanin; Lamivudine/zidovudine; Stavudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- 20 Oct 2005 New trial record.